Welcome to our dedicated page for bli news (Ticker: bli), a resource for investors and traders seeking the latest updates and insights on bli stock.
Berkeley Lights, Inc. operates as a leading biotechnology company dedicated to providing cutting-edge technology solutions for single-cell manipulation. The company's innovative platform facilitates advancements in biopharma, diagnostics, and life science research. Berkeley Lights leverages its proprietary OptoSelect™ technology to enable precise control over biological processes at the single-cell level.
Headquartered in the United States, Berkeley Lights serves a global customer base, including leading pharmaceutical companies, research institutions, and diagnostics firms. The company's technology empowers researchers to discover new drugs, create better diagnostics, and develop innovative therapies.
One of the notable recent achievements of Berkeley Lights is the expansion of its platform capabilities, enhancing the efficiency and accuracy of single-cell analysis. The company has also formed strategic partnerships with key industry players to drive further innovation and market reach.
Financially, Berkeley Lights continues to show robust performance, with steady revenue growth and strategic investments in research and development. The company is committed to maintaining a strong financial position to support its mission of advancing human health through groundbreaking biotechnological solutions.
Current projects include the development of advanced cell therapy applications and expanding the use of their technology in various research and clinical settings. These projects highlight Berkeley Lights' commitment to pushing the boundaries of what's possible in biotechnology.
Overall, Berkeley Lights, Inc. stands at the forefront of biotechnology, offering unparalleled solutions for single-cell research and manipulation. The company's dedication to innovation and quality makes it a significant player in the life sciences sector.
Berkeley Lights, Inc. (Nasdaq: BLI) is set to report its first quarter 2022 financial results on May 9, 2022, after market close. A conference call will follow at 1:30 p.m. PT/4:30 p.m. ET. The event will be webcast live, with access on the Company’s website and archived for later viewing. Berkeley Lights specializes in digital cell biology, creating platforms for the rapid development of biotherapeutics and cell-based products, providing an integrated solution for cell characterization.
Berkeley Lights, Inc. (Nasdaq: BLI) has appointed Lucas Vitale as the new Chief Human Resources Officer, effective immediately. Vitale brings over 20 years of HR experience in the life sciences sector. Previously, he was SVP of HR at Arena Pharmaceuticals and CHRO at NuVasive, where he developed global HR strategies and diversity initiatives. CEO Dr. Siddhartha Kadia emphasized that Vitale’s leadership will enhance team development and support the company's strategic growth. This appointment seeks to strengthen Berkeley Lights’ human capital, crucial for its expansion in biotherapeutics and cell-based product markets.
Berkeley Lights (Nasdaq: BLI) has partnered with Vestaron Corporation to develop peptide-based crop protection solutions, enhancing safety and efficacy for the global food supply. Utilizing Berkeley Lights' high-throughput screening services, this collaboration aims to create novel pesticidal peptides with minimal toxicity to non-target organisms. The partnership, the third in agriculture for Berkeley Lights in under a year, highlights a shift towards sustainable agricultural practices, addressing resistance issues faced by growers worldwide.
Berkeley Lights (Nasdaq: BLI) has appointed Dr. Siddhartha Kadia as its new CEO, effective immediately, succeeding Eric D. Hobbs. Dr. Kadia brings over 20 years of industry experience, previously serving as CEO of EAG Laboratories. The Board believes his expertise will enhance shareholder value. Dr. Hobbs will focus on the Antibody Therapeutics business. The company also announced that CFO Kurt Wood will leave for a role outside biotech, remaining in an advisory capacity until the end of April 2022. Berkeley Lights aims to continue its growth in digital cell biology.
Berkeley Lights, Inc. (BLI) will participate in the Festival of Biologics from March 9-11, 2022, at Marriott Marquis San Diego. At booth #39, they will showcase their Berkeley Lights Platform and antibody discovery workflows, specifically the Opto™ Plasma B Discovery workflow. Kent Lee, the company's antibody discovery product manager, will present on March 10 about accelerating lead molecule discovery against difficult targets using their innovative Beacon Optofluidic system.
Berkeley Lights, Inc. (BLI) announced a software upgrade to its Suite, enhancing its Cell Analysis, Image Analyzer, and Assay Analyzer tools for the Beacon and Lightning Systems. The update aims to streamline workflows in antibody discovery and cell therapy by providing quicker loading times, improved automation, and refined data analysis capabilities. Key features include enhanced sample recovery, montage data viewing, new trellis plot functionality, and a more intuitive interface.
This upgrade supports researchers in achieving faster results and cost-effective sample management.
Berkeley Lights, Inc. (Nasdaq: BLI) announced its participation in the Cowen 42nd Annual Health Care Conference, occurring virtually from March 7-9, 2022. Eric Hobbs, Ph.D., CEO, will join the Synthetic Biology Enabling Technologies Panel on March 7 at 10:30 a.m. ET. Furthermore, management will present in a fireside chat on March 8 at 12:50 p.m. ET. Interested parties can access the live broadcast through the company’s website.
Berkeley Lights (BLI) reported a full year 2021 revenue of $85.4 million, exceeding initial expectations, with a 33% increase over the previous year. The fourth quarter revenue reached $23.2 million, a 7% rise year-over-year. Installed platforms grew 48% to 111, and strategic partnerships revenue surged more than three-fold to $19.9 million. Recurring revenue also increased 38% to $19.2 million. The company anticipates a 30% revenue growth for 2022 compared to 2021.
Berkeley Lights, Inc. (BLI) will report its financial results for Q4 and FY 2021 on February 24, 2022, before market open. Management will host a conference call at 5:30 a.m. PT / 8:30 a.m. ET, which will be accessible via the company's website. Berkeley Lights specializes in digital cell biology, offering a platform that accelerates the development of biotherapeutics and cell-based products. Their integrated solution includes proprietary consumables and advanced automation, aimed at setting industry standards for cell characterization.
Berkeley Lights, a leader in digital cell biology, will participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 15 to 17, 2022. Management is scheduled to present on February 16 at 9:00 a.m. PT / 12:00 p.m. ET. The conference is exclusive to BTIG clients. Berkeley Lights focuses on rapid development and commercialization of biotherapeutics and cell-based products through its advanced platform, which captures information from thousands of single cells. Forward-looking statements from the company carry inherent risks and uncertainties.
FAQ
What is the market cap of bli (bli)?
What does Berkeley Lights, Inc. do?
Who are the customers of Berkeley Lights?
What is OptoSelect™ technology?
Has Berkeley Lights achieved any recent milestones?
What are Berkeley Lights' current projects?
How is Berkeley Lights performing financially?
Where is Berkeley Lights headquartered?
What impact does Berkeley Lights have on the biotechnology sector?
What is the significance of their technology in biopharma?
Who are some of Berkeley Lights' strategic partners?
